RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2011; 136(17): 898-903
DOI: 10.1055/s-0031-1275826
DOI: 10.1055/s-0031-1275826
Übersicht | Review article
Endokrinologie, Osteologie
© Georg Thieme Verlag KG Stuttgart · New York
Neue Targets in der Osteoporosetherapie
New targets for treatment of osteoporosisWeitere Informationen
Publikationsverlauf
eingereicht: 15.11.2010
akzeptiert: 14.4.2011
Publikationsdatum:
26. April 2011 (online)
![](https://www.thieme-connect.de/media/dmw/201117/lookinside/thumbnails/10.1055-s-0031-1275826-1.jpg)
Schlüsselwörter
Osteoporose - Osteoklastogenese - Zielmoleküle
Keywords
osteoporosis - osteoclastogenesis - target molecules
Literatur
- 1 Bodine P V, Stauffer B, Ponce-de-Leon H. et al . A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone. 2009; 44 1063-1068
- 2 Bone H G, McClung M R, Roux C. et al . Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010; 25 937-947
- 3 Chantry A D, Heath D, Mulivor A W. et al . Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. J Bone Miner Res. 2010; 25 2357-2570
- 4 Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010; 9 804-820
- 5 Eisman J A, Bone H G, Hosking D J. et al . Odanacatib in the treatment of postmenopausal women with low bone mineral density. J Bone Miner Res. 2011; 26 242-251
- 6 Fajardo R J, Manoharan R K, Pearsall R S. et al . Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone. 2010; 46 64-71
- 7 Henriksen D B, Alexandersen P, Hartmann B. et al . Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone. 2007; 40 723-729
- 8 Henriksen D B, Alexandersen P, Hartmann B. et al . Four-month treatment with GLP-2 significantly increases hip BMD. Bone. 2009; 45 833-842
- 9 Hofbauer L C, Kuhne C A, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact. 2004; 4 268-725
- 10 Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep. 2010; 8 163-167
- 11 Jakob F, Seefried L, Ebert R. Pathophysiologie des Knochenstoffwechsels. Internist. 2008; 49 1159-1164
- 12 Jakob F. Metabolische Knochenerkrankungen. Internist. 2007; 48 1101-1107
- 13 Jakob F, Benisch P, Klotz B. et al . Sexualsteroide in der Homöostase des Knochens. Osteologie/Osteology. 2010; 2 105-110
- 14 Jensen E D, Gopalakrishnan R, Westendorf J J. Regulation of gene expression in osteoblasts. Biofactors. 2010; 36 25-32
- 15 Kamiya N, Kobayashi T, Mochida Y. et al . Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010; 25 200-210
- 16 Kartal-Kaess M, Shore E M. et al . Fibrodysplasia ossificans progressiva (FOP): watch the great toes!. Eur J Pediatr. 2010; 169 1417-1421
- 17 Kasten P, Beyen I, Bormann D, Luginbuhl R, Ploger F, Richter W. The effect of two point mutations in GDF-5 on ectopic bone formation in a beta-tricalciumphosphate scaffold. Biomaterials. 2010; 31 3878-3884
- 18 Koncarevic A, Cornwall-Brady M, Pullen A. et al . A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010; 151 4289-4300
- 19 Kramer I, Halleux C, Keller H. et al . Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30 3071-3085
- 20 Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab. 2010; 21 237-244
- 21 Kramer I, Loots G G, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25 178-189
- 22 Lewiecki E M. Denosumab – an emerging treatment for postmenopausal osteoporosis. Expert Opin Biol Ther. 2010; 10 467-476
- 23 Lotinun S, Pearsall R S, Davies M V. et al . A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010; 46 1082-1088
- 24 Marie P J. The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone. 2010; 46 571-576
- 25 Mason J J, Williams B O. SOST and DKK: Antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos. 2010; 2010 460 120
- 26 Matsumoto T, Abe M. TGF-beta-related mechanisms of bone destruction in multiple myeloma. Bone. 2011; 48 129-134
- 27 Moester M J, Papapoulos S E, Lowik C W, van Bezooijen R L. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87 99-107
- 28 Nakashima A, Katagiri T, Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem. 2005; 280 37 660-37 668
- 29 Raggatt L J, Partridge N C. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010; 285 25 103-25 108
- 30 Ralston S H, Uitterlinden A G. Genetics of osteoporosis. Endocr Rev. 2010; 31 629-662
- 31 Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab. Nat Rev Drug Discov. 2010; 9 591-592
- 32 Saidak Z, Brazier M, Kamel S, Mentaverri R. Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications. Mol Pharmacol. 2009; 76 1131-1144
- 33 Saylor P J, Smith M R. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010; 13 20-27
- 34 Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009; 19 219-233
- 35 Shore E M, Kaplan F S. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010; 6 518-527
- 36 Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009; 20 343-355
- 37 Tamura M, Nemoto E, Sato M M, Nakashima A, Shimauchi H. Role of the Wnt signaling pathway in bone and tooth. Front Biosci (Elite Ed). 2010; 2 1405-1413
- 38 Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs. 2010; 19 995-1005
- 39 Trivedi R, Mithal A, Chattopadhyay N. Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med. 2010; 10 14-28
- 40 Wagner D O, Sieber C, Bhushan R, Borgermann J H, Graf D, Knaus P. BMPs: from bone to body morphogenetic proteins. Sci Signal. 2010; 3 mr1
- 41 Walsh D W, Godson C, Brazil D P, Martin F. Extracellular BMP-antagonist regulation in development and disease. Trends Cell Biol. 2010; 20 244-256
- 42 Walsh J S, Henriksen D B. Feeding and bone. Arch Biochem Biophys. 2010; 503 11-19
- 43 Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma. 2010; 51 213-220
- 44 Jakob F, Benisch P, Bhushan R, Ebert R, Seefried L, Schieker M, Ignatius A. Zelluläre Defekte und Regulationsstörungen bei der Heilung osteoporotischer Frakturen. Osteologie. 2011; 20 23-28
- 45 Seefried L , Ebert R, Müller-Deubert S. et al . Mechanotransduktion im Alter und bei Osteoporose. Osteologie. 2010; 19 232-239
Prof. Dr. Franz Jakob
Orthopädisches Zentrum für Muskuloskelettale
Forschung
Brettreichstraße 11
97074
Würzburg
Telefon: 0931/8031580
Fax: 0931/8031599
eMail: f-jakob.klh@uni-wuerzburg.de